Company Website: https://senseibio.com
BOSTON -- (Business Wire)

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that Company management will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16^th, 2026 at 12:45 p.m. ET.

The live webcast of the presentation may be accessed via the Events and Presentations section of the Sensei website at investors.senseibio.com. A replay of the webcast will be available for approximately 90 days following the event.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. Following the acquisition of Faeth Therapeutics, Sensei's lead program is PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. Sensei is also completing a Phase 1/2 trial of solnerstotug, its V-domain Ig suppressor of T cell activation (VISTA) inhibitor, in patients with advanced solid tumors. Sensei intends to use its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, please visit www.senseibio.com and follow the company on X @SenseiBio and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260409316060/en/

Contacts:

Investor Contact:
Stephanie Ascher, Precision AQ
Stephanie.ascher@precisionaq.com

Media Contact:
Patrick Schmidt, Consort Partners
senseibio@consortpartners.com

Source: Sensei Biotherapeutics, Inc.